Claims for Patent: 11,931,459

Summary for Patent: 11,931,459

Title:	Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions
Abstract:	In some embodiments provided herein is a method of treating pain, the method comprising administering to the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.
Inventor(s):	Roy Winston
Assignee:	Pacira Pharmaceuticals Inc
Application Number:	US17/697,261
Patent Claims:	1. A method of treating pain in a pediatric subject aged 12 to <17 years undergoing spine surgery, the method comprising: administering to the subject about 4 milligrams of a pharmaceutical composition per kilogram of the subject's body weight, the pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome. 2. The method of claim 1, wherein the pharmaceutical composition is administered by local infiltration prior to wound closure. 3. The method of claim 2, wherein the plasma Cmax of bupivacaine in the subject following spine surgery is about 225 ng/mL to about 400 ng/mL. 4. The method of claim 3, wherein the plasma Cmax of bupivacaine in the subject following spine surgery is about 246 ng/mL to about 296 ng/mL. 5. The method of claim 2, wherein the plasma Tmax of bupivacaine in the pediatric subject is about 1.1 hours following administration of the pharmaceutical composition to the subject. 6. The method of claim 5, wherein the plasma Tmax of bupivacaine in the pediatric subject is about 1.1 hours and about 18.0 hours following administration of the pharmaceutical composition to the subject. 7. The method of claim 1, wherein the pharmaceutical composition consists essentially of: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase consisting essentially of bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome. 8. A method of treating pain in a pediatric subject aged 6 to <12 years undergoing spine surgery, the method comprising: administering to the subject about 4 milligrams of a pharmaceutical composition per kilogram of the subject's body weight, the pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome. 9. The method of claim 8, wherein the pharmaceutical composition is administered by local infiltration prior to wound closure. 10. The method of claim 9, wherein the plasma Cmax of bupivacaine in the subject following spine surgery is about 250 ng/mL to about 440 ng/mL. 11. The method of claim 10, wherein the plasma Cmax of bupivacaine in the subject following spine surgery is 320 ng/mL. 12. The method of claim 8, wherein the Tmax of bupivacaine in the pediatric subject is about 2.4 hours following administration of the pharmaceutical composition to the subject. 13. The method of claim 11, wherein the Tmax of bupivacaine in the pediatric subject is about 2.4 hours and about 15.3 hours following administration of the pharmaceutical composition to the subject. 14. The method of claim 7, wherein the pharmaceutical composition consists essentially of: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase consisting essentially of bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome. 15. A method of treating pain in a pediatric subject aged 6 to <17 years undergoing cardiac surgery, the method comprising: administering to the subject about 4 milligrams of a pharmaceutical composition per kilogram of the subject's body weight, the pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome. 16. The method of claim 15, wherein the pharmaceutical composition is administered by local infiltration prior to wound closure. 17. The method of claim 16, wherein the pediatric subject is aged 6 to <12 years. 18. The method of claim 17, wherein the Cmax of bupivacaine in the subject following cardiac surgery is about 250 ng/mL to about 1300 ng/mL. 19. The method of claim 17, wherein the Tmax of bupivacaine in the pediatric subject is about 0.4 hours following administration of the pharmaceutical composition to the subject. 20. The method of claim 19, wherein the Tmax of bupivacaine in the pediatric subject is about 0.4 hours and about 30.1 hours following administration of the pharmaceutical composition to the subject. 21. The method of claim 16, wherein the pediatric subject is aged 12 to <17 years. 22. The method of claim 15, wherein the pharmaceutical composition consists essentially of: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase consisting essentially of bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.